{"id":"W3089254712","doi":"10.1016/j.ygyno.2020.09.006","title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Université de Sherbrooke","funders":"Genentech; Medac; Eisai; Merck KGaA; Clovis Oncology; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Takeda Oncology; Amgen; Pfizer; PharmaMar; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Placebo; Ovarian cancer; Oncology; Internal medicine; Nova (rocket); Term (time); Gynecology; Cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001813753,0.0008409498,0.002456211,0.00022984,0.0002638079,0.0009554993,0.0005724776,0.001021333,0.002345884],"category_scores_gemma":[0.002162501,0.0003193321,0.002627358,0.000315779,0.000715393,0.001057372,0.0003484861,0.003031296,0.0004398196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006219257,"about_ca_system_score_gemma":0.000581149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003845239,"about_ca_topic_score_gemma":0.001076398,"domain_scores_codex":[0.9993574,0.0003525771,0.00004222386,0.000113579,0.0000526193,0.00008155885],"domain_scores_gemma":[0.9989551,0.0003341031,0.0003580982,0.00009434376,0.00004359552,0.0002147048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9142172,0.002829491,0.00595896,0.0008353747,0.004083205,0.0001151294,0.0000824799,0.001282521,0.004453586,0.0001410417,0.00136542,0.06463566],"study_design_scores_gemma":[0.7095595,0.22693,0.04723858,0.0002003494,0.005968121,0.000551861,0.0001405634,0.002124725,0.00186282,0.001193419,0.004150796,0.00007920223],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794613,0.01615036,0.0004185252,0.0007439021,0.0003088247,0.0002379325,0.0009962465,0.00006003455,0.001622849],"genre_scores_gemma":[0.9905651,0.004599331,0.0003846667,0.0008195709,0.000319423,0.0002298413,0.001476336,0.00002252785,0.001583333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002456211,"threshold_uncertainty_score":0.009592175,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06628635318853937,"score_gpt":0.3559843716562436,"score_spread":0.2896980184677043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}